Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Debate 5A Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
- Debate 5B Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
- Chapter 6A In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?
- Debate 6B In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?
- Debate 7A Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?
- Debate 7B Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?
- Debate 8A Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?
- Debate 8B Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?
- Debate 9A How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?
- Debate 9B How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?
- Debate 10A Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?
- Debate 10B Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?
- Debate 11A Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?
- Debate 11B Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?
- Debate 12A Should Minimally Invasive Modalities be Routinely/Uniformly Utilized for Assessment of Resectability prior to Attempted Primary Debulking in Patients with Advanced Ovarian Cancer?
- Debate 12B Should Laparoscopic Modalities be Routinely Utilized for Assessment of Resectability prior to Attempted Primary Debulking in Patients with Advanced Ovarian Cancer?
- Debate 13A Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Procedures for Patients with Advanced Ovarian Cancer?
- Debate 13B Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Procedures for Patients with Advanced Ovarian Cancer?
- Debate 14A Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian Cancer?
- Debate 14B Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian Cancer?
- Debate 15A Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?
- Debate 15B Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?
- Debate 16A What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?
- Debate 16B What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?
- Debate 17A When is the Best Time to Use PARP Inhibitors for Maintenance?
- Debate 17B When is the Best Time to Use PARP Inhibitors for Maintenance?
- Debate 18A What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced epithelial ovarian cancer? Bevacizumab
- Debate 18B What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced epithelial ovarian cancer?
- Debate 19A What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer
- Debate 19B What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer?
- Debate 20A Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreduction prior to Receiving Platinum-containing Second-line Chemotherapy?
- Debate 20B Should All Patients with Platinum-sensitive Recurrent Ovarian Cancer be Considered for Secondary Cytoreduction prior to Receiving Second-line Platinum Chemotherapy?
- Debate 21A Should Tertiary Debulking for Patients with Recurrent Ovarian Cancer be Performed?
- Debate 21B Should Tertiary Debulking be Performed for Patients with Recurrent Ovarian Cancer?
- Debate 22A Is there a Role for Immunotherapy in Ovarian Cancer?
- Debate 22B Is there a Role for Immunotherapy in Ovarian Cancer?
- Debate 23A What is the Best Management Option for Malignant Bowel Obstruction?
- Debate 23B What is the Best Management Option for Malignant Bowel Obstruction?
- Debate 24A What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?
- Debate 24B What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?
- Debate 25A What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?
- Debate 25B What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?
- Debate 26A What is the Best Management Strategy for a Recurrent Granulosa Cell Tumor?
- Debate 26B What is the Best Management Strategy for Recurrent Granulosa Cell Tumor?
- Debate 27A Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?
- Debate 27B Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 26B - What is the Best Management Strategy for Recurrent Granulosa Cell Tumor?
Chemotherapy
from Section III - Ovarian Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Debate 5A Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
- Debate 5B Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
- Chapter 6A In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?
- Debate 6B In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?
- Debate 7A Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?
- Debate 7B Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?
- Debate 8A Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?
- Debate 8B Should Stage IC Mucinous Ovarian Carcinoma be Managed by Observation or Adjuvant Chemotherapy?
- Debate 9A How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?
- Debate 9B How Many Cycles of Adjuvant Chemotherapy Should be Administered to Patients with High-risk Stage I Epithelial Ovarian Cancer?
- Debate 10A Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?
- Debate 10B Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?
- Debate 11A Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?
- Debate 11B Should an Attempt at Aggressive Cytoreduction be Made for all Surgical Candidates with Advanced Ovarian Cancer prior to Treatment with Adjuvant Chemotherapy?
- Debate 12A Should Minimally Invasive Modalities be Routinely/Uniformly Utilized for Assessment of Resectability prior to Attempted Primary Debulking in Patients with Advanced Ovarian Cancer?
- Debate 12B Should Laparoscopic Modalities be Routinely Utilized for Assessment of Resectability prior to Attempted Primary Debulking in Patients with Advanced Ovarian Cancer?
- Debate 13A Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Procedures for Patients with Advanced Ovarian Cancer?
- Debate 13B Should Enlarged Supradiaphragmatic Lymph Nodes be Routinely Removed during Debulking Surgery Procedures for Patients with Advanced Ovarian Cancer?
- Debate 14A Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian Cancer?
- Debate 14B Is there a Role for Hyperthermic Intraperitoneal Chemotherapy in Front-line Therapy for Ovarian Cancer?
- Debate 15A Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?
- Debate 15B Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?
- Debate 16A What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?
- Debate 16B What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?
- Debate 17A When is the Best Time to Use PARP Inhibitors for Maintenance?
- Debate 17B When is the Best Time to Use PARP Inhibitors for Maintenance?
- Debate 18A What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced epithelial ovarian cancer? Bevacizumab
- Debate 18B What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced epithelial ovarian cancer?
- Debate 19A What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer
- Debate 19B What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer?
- Debate 20A Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreduction prior to Receiving Platinum-containing Second-line Chemotherapy?
- Debate 20B Should All Patients with Platinum-sensitive Recurrent Ovarian Cancer be Considered for Secondary Cytoreduction prior to Receiving Second-line Platinum Chemotherapy?
- Debate 21A Should Tertiary Debulking for Patients with Recurrent Ovarian Cancer be Performed?
- Debate 21B Should Tertiary Debulking be Performed for Patients with Recurrent Ovarian Cancer?
- Debate 22A Is there a Role for Immunotherapy in Ovarian Cancer?
- Debate 22B Is there a Role for Immunotherapy in Ovarian Cancer?
- Debate 23A What is the Best Management Option for Malignant Bowel Obstruction?
- Debate 23B What is the Best Management Option for Malignant Bowel Obstruction?
- Debate 24A What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?
- Debate 24B What is the Optimal Chemotherapy Regimen for Ovarian Germ-cell Tumors?
- Debate 25A What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?
- Debate 25B What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?
- Debate 26A What is the Best Management Strategy for a Recurrent Granulosa Cell Tumor?
- Debate 26B What is the Best Management Strategy for Recurrent Granulosa Cell Tumor?
- Debate 27A Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?
- Debate 27B Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
Patients with early-stage granulosa cell tumors (IA or IB) may be treated with surgical therapy alone and expect an excellent prognosis. Patients with stage IC or greater disease, recurrent granulosa cell tumors, and sub-optimally reduced disease may benefit from adjuvant chemotherapy. The type of adjuvant chemotherapy has been controversial and varies based on clinical guidelines. The National Comprehensive Cancer Network (NCCN) guidelines recommend platinum-based chemotherapy and endorses paclitaxel and carboplatin (PC), etoposide and cisplatin, or bleomycin, etoposide, cisplatin (BEP). In this debate the following article, we prefer the authors support the use of paclitaxel plus carboplatin based on (1) BEP lacks durable activity, (2) PC demonstrates favorable outcomes in a retrospective analysis, (3) PC has a better safety profile compared to BEP, (4) the dosing regimen for PC is more convenient, and (5) there is insufficient data comparing PC to BEP.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 155 - 157Publisher: Cambridge University PressPrint publication year: 2023
References
Gershenson, DM, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 1996;87(4):527–531.CrossRefGoogle ScholarPubMed
Homesley, HD, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 1999;72(2):131–137.CrossRefGoogle ScholarPubMed
Brown, J, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 2005;97(2):489–496.CrossRefGoogle ScholarPubMed
Pautier, P, et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer 2008;18(3):446–452.CrossRefGoogle ScholarPubMed
Burton, ER, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016;140(1):48–52.CrossRefGoogle ScholarPubMed
Ray-Coquard, I, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol 2020; 6(12):1923–1930.CrossRefGoogle ScholarPubMed
Brown, J, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 2014;120(3):344–351.CrossRefGoogle ScholarPubMed
van Meurs, HS, et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol 2014;134(1):196–205.CrossRefGoogle ScholarPubMed
Mills, AM, et al. Emerging biomarkers in ovarian granulosa cell tumors. Int J Gynecol Cancer 2019;29(3):560–565.CrossRefGoogle ScholarPubMed
Pierini, S, et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight 2020;5(16):e136773.CrossRefGoogle ScholarPubMed